Disease-specific survival following the brachytherapy management of prostate cancer

Conclusions: The 10-year DSS rate supports the efficacy of brachytherapy. Patients dying with disease within 10 years after treatment harbor inherently aggressive cancer with high Gleason scores and short DT.